Xcout Intel
ABSCINT
ABSCINT is a clinical-stage biotechnology company that develops platform production processes for rapid creation of cold kits for molecular imaging in oncology and immunology. Headquartered in Belgium, the privately held firm focuses on innovative diagnostic and therapeutic applications using single-domain antibodies.
Subscribe to see ABSCINT’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ABSCINT at a glance
ABSCINT is a diagnostics company headquartered in Belgium. Its most recent funding round raised $3M in September 2023. Xcout tracks 17 named people at ABSCINT, including Karine Clauwaert (Chief Executive Officer).
ABSCINT leadership
- Karine ClauwaertChief Executive Officer
- Koen DewaelePresident of the Board
- Martine VandermarliereChief Technical Officer
- Philippe VanwolleghemChief Quality and Regulatory Officer
- Catherine SkaClinical Operations and QA Manager
- Dieter FrijnsClinical Operations and Medical Affairs Lead
11 more named people on record for ABSCINT, with roles, board committees and tenure — see the full roster →
ABSCINT funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $3M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
ABSCINT competitors
A few of ABSCINT's closest competitors — see the full list of competitors and alternatives →
ImaginAb, Inc. is a global biotechnology company headquartered in California, with operations in Los Angeles and San Diego. It focuses on developing next-generation imaging and radiopharmaceutical products for cancer immunology.
On Target Laboratories, Inc. is a biotechnology company founded in 2010 and headquartered in West Lafayette, Indiana. It discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery.
Spago Nanomedical is a clinical-stage pharmaceutical company that develops precision nanomedicine products for the diagnosis and treatment of cancer and other severe diseases. Its pipeline includes Tumorad, a targeted radionuclide therapy for various cancers, and SpagoPix, a polymeric contrast agent designed to improve the precision of MRI diagnostics.
Merus N.V. is a clinical-stage oncology company that discovers and develops antibody treatments for cancer using its proprietary Multiclonics platform. The company serves patients with cancer by advancing innovative therapeutic pipelines. Merus operates as part of Genmab.
Anaveon is a late-stage preclinical biotechnology company based in Basel, Switzerland, focused on developing engineered antibodies for immunotherapy.
Precirix is a clinical-stage biotechnology company dedicated to improving outcomes by developing precision radiopharmaceuticals for cancer therapy. Operating within the biotechnology research sector, the Brussels-based firm launched products such as CAM-FAP-Ga.
Get ABSCINT's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ABSCINT in Xcout Intel
- 17 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access